MedDRA preferred term · the product was used past its expiry date

Expired product administered: adverse event reports recording this term

32,743 reports to FDA record it, 2006–2026; 0.2% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

32,743
reports recording the term: 0.2% of all reports; 1,804
reports, 12 months to June 2026: 1,854 in the 12 months before; 16.2%
marked serious by the reporter: 57.4% across all reports; 0.7%
record death among outcomes, as reported: 9.1% across all reports

"Expired product administered" (in plain words, the product was used past its expiry date) is a MedDRA preferred term recorded in 32,743 adverse event reports received by FDA, 0.2% of the database, from February 2006 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

1,804 reports recorded it in the 12 months to June 2026, close to the 1,854 of the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 16.2% are marked serious, 0.7% include death among the outcomes and 5.6% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are MiraLAX, Aleve and Ventolin Hfa. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
MiraLAX	Osmotic laxative	1,524	4%
Aleve	Nonsteroidal anti-inflammatory drug	1,159	2.4%
Ventolin Hfa	beta2-Adrenergic agonist	706	3.1%
Humalog	Insulin analog	635	0.9%
Claritin	—	597	3.1%
Diclofenac sodium	Nonsteroidal anti-inflammatory drug	560	1.1%
Advair Diskus	Corticosteroid	554	2.7%
Sterile diluent	Insulin analog	416	12.9%
Loratadine	—	379	4.3%
Zyrtec	Histamine-1 receptor antagonist	359	1.8%
Albuterol sulfate	beta2-Adrenergic agonist	326	0.7%
Minoxidil	Arteriolar vasodilator	326	1.1%
Restasis	Calcineurin inhibitor immunosuppressant	320	1.8%
Womens Rogaine Unscented	Arteriolar vasodilator	317	2.8%
Lyrica	—	308	0.3%
Imodium Multi-Symptom Relief	—	301	5.6%
Ibuprofen	Nonsteroidal anti-inflammatory drug	293	0.4%
Mens Rogaine Extra Strength	—	278	2.2%
Cetirizine hydrochloride	Histamine-1 receptor antagonist	265	1.4%
Imodium A-D	Opioid agonist	260	7.5%
TYLENOL Extra Strength	—	245	3.1%
Paxlovid	—	231	0.4%
Loperamide hydrochloride	Opioid agonist	229	4.4%
Lantus Solostar	Insulin analog	226	0.5%
Insulin glargine	Insulin analog	221	0.8%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.2% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Nonsteroidal anti-inflammatory drug	2,936	0.5%	0.1%
Insulin analog	2,176	0.8%	0.6%
Corticosteroid	1,804	0.2%	0.1%
Osmotic laxative	1,774	1.4%	0%
Histamine-1 receptor antagonist	1,142	0.8%	0.2%
beta2-Adrenergic agonist	1,128	1.2%	0.4%
Cholinergic nicotinic agonist	686	1.3%	1.3%
Opioid agonist	661	0.1%	0%
Arteriolar vasodilator	643	1.5%	0.6%
Expectorant	577	1.1%	2.4%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.7%228

2 to 111.9%622

12 to 171%333

18 to 446.9%2,252

45 to 6413%4,246

65 to 7411.8%3,867

75 and over13.6%4,469

Age not given51.1%16,726

Patient sex

Female56.9%18,647

Male30.5%9,986

Not given12.6%4,110

Grey bar: all 20,646,523 reports in the database. 94.2% of these reports give the United States as the country.

Questions about "Expired product administered"

What does "Expired product administered" mean in an adverse event report?

In plain language: the product was used past its expiry date. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record expired product administered?

32,743 reports through June 2026 (0.2% of all reports), 1,804 of them in the latest 12 months.

Which drugs appear most often in these reports?

MiraLAX (1,524), Aleve (1,159), Ventolin Hfa (706), Humalog (635) and Claritin (597). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.